Attached files
file | filename |
---|---|
8-K - COLLABRX, INC 8-K 1-9-2013 - Rennova Health, Inc. | form8k.htm |
Exhibit 99.1
CollabRx, Inc.
Informing Next Generation Healthcare
This presentation and the accompanying commentary include forward-looking
statements about CollabRx’ anticipated results that involve risks and uncertainties. Some
of the information contained in this presentation, including, but not limited to,
statements as to industry trends and CollabRx’ plans, objectives, expectations and
strategy for its business, contains forward-looking statements that are subject to risks
and uncertainties that could cause actual results or events to differ materially from those
expressed or implied by such forward-looking statements. Any statements that are not
statements of historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or
future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar
expressions, identify certain of these forward-looking statements. Important factors
which could cause actual results to differ materially from those in the forward-looking
statements are detailed in filings made by CollabRx with the Securities and Exchange
Commission. CollabRx undertakes no obligation to update or revise any such forward-
looking statements to reflect subsequent events or circumstances.
statements about CollabRx’ anticipated results that involve risks and uncertainties. Some
of the information contained in this presentation, including, but not limited to,
statements as to industry trends and CollabRx’ plans, objectives, expectations and
strategy for its business, contains forward-looking statements that are subject to risks
and uncertainties that could cause actual results or events to differ materially from those
expressed or implied by such forward-looking statements. Any statements that are not
statements of historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or
future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar
expressions, identify certain of these forward-looking statements. Important factors
which could cause actual results to differ materially from those in the forward-looking
statements are detailed in filings made by CollabRx with the Securities and Exchange
Commission. CollabRx undertakes no obligation to update or revise any such forward-
looking statements to reflect subsequent events or circumstances.
2
Copyright Collabrx, Inc. 2012
NASDAQ CM: CLRX
¡ CollabRx’ Identity, Technology and Approach
¡ Platform for Knowledge Integration
¡ Products - Released and Under Development
¡ Healthcare Big Data Landscape
¡ Product Examples
¡ History, Management Team, Investment
Thesis
Thesis
¡ Contacts
Copyright Collabrx, Inc. 2012
NASDAQ CM: CLRX
3
¡ Data Analytics Company, founded 2008
§ NASDAQ CM: July 12, 2012 through merger
¡ Product-Driven, using a unique combination of
Experts and Expert Systems to create a Proprietary
Knowledgebase
Experts and Expert Systems to create a Proprietary
Knowledgebase
¡ Inform clinical decision-making with up-to-date,
actionable information on:
actionable information on:
§ Biomarkers
§ Clinical Trials
§ Diagnostic Tests
§ Approved and Investigational New Drugs
¡ Focused today in Oncology for cancer diagnostics and
treatment planning
treatment planning
4
NASDAQ CM: CLRX
Copyright Collabrx, Inc. 2012
¡ Democratizing information by widely
distributing KOL-based insights
distributing KOL-based insights
¡ “Agnostic” to any particular diagnostic test -
focused on relevant biomarkers, therapies,
drugs and trials
focused on relevant biomarkers, therapies,
drugs and trials
¡ Technology platform allows scaling in all
dimensions as new biomarkers identified
dimensions as new biomarkers identified
¡ Easy-to-use apps are key to accessibility and
usability
usability
¡ Flexible and adaptable software-centric
company
company
Copyright Collabrx, Inc. 2012
NASDAQ CM: CLRX
5
Copyright Collabrx, Inc. 2012
NASDAQ CM: CLRX
6
Disease Targets
Drugs
Biomarkers
Clinical Trials
KNOWLEDGE INTEGRATION
Basic
Analytic
Synthetic
Capture and Integrate
Acquire or License
Create
Over 75 medical and scientific advisors
from leading institutions
from leading institutions
"We're pleased to partner with
CollabRx to leverage the Internet
and social media to improve
cancer treatment planning in
melanoma and beyond.”
CollabRx to leverage the Internet
and social media to improve
cancer treatment planning in
melanoma and beyond.”
“Our collaboration with CollabRx
helps us deliver on our mission to
serve patients and fosters greater
communication between patients and
physicians which is vital to successful
treatment.”
helps us deliver on our mission to
serve patients and fosters greater
communication between patients and
physicians which is vital to successful
treatment.”
7
NASDAQ CM: CLRX
Copyright Collabrx, Inc. 2012
Copyright Collabrx, Inc. 2012
NASDAQ CM: CLRX
8
Medical and Scientific Content
Dynamically updated
Best practice insights
Clinically relevant interpretations
Software and IT
Content delivery systems (“apps”)
Knowledge management systems
Decision support dashboards
Tools and Services
Artificial intelligence-based analytics
Interpretation of Big Data
Business intelligence (Pharma/Biotech)
Copyright Collabrx, Inc. 2012
NASDAQ CM: CLRX
9
Physician / Patient Care Team
Laboratory / Treatment Team
Therapy Finder Apps
Lung, Melanoma,
Colorectal,
Colorectal,
Metastatic Breast,
Prostate, Pancreatic,
Acute Leukemia,
Sarcoma (including GIST),
GBE
Clinical Trial Matching App
Biomarker Reference Tool
Interpretation Portal
Path Lab App
Molecular
Diagnostics
Diagnostics
Decision Support
Workflow and
Clinical
Course Issues
Clinical
Course Issues
Lab Dashboard (EMR)
Clinical Interpretation App
Analytics on collected data - Mobile - Social Networking
Copyright Collabrx, Inc. 2012
NASDAQ CM: CLRX
10
Physician / Patient Care Team
Laboratory / Treatment Team
Sponsored Apps distributed
through On-Line Media:
through On-Line Media:
*Based on reimbursed molecular PGx cancer test data from United Healthcare and
**Market Research.com #Internal Estimates Phase II/III no approved indications
**Market Research.com #Internal Estimates Phase II/III no approved indications
Path Lab Product only
distributed by CollabRx:
distributed by CollabRx:
Annual: 750,000 tests*
Ave. Price / Test ~ $3,000
Ave. Price / Report ~ $100-$200
TAM (today): $75M - $150M
Growth Rate: ~47% pa**
TAM (5 yr): $350M - $700M
Pharma Pre-Launch Marketing
budget per drug: ~ $50M #
budget per drug: ~ $50M #
Number of Drugs in Pipeline for
Common Incident Cancers ~ 50
Common Incident Cancers ~ 50
% of Budget to On-Line 10%
TAM: $250M
Copyright Collabrx, Inc. 2012
NASDAQ CM: CLRX
11
12
Clinical
Support
Support
Public
Awareness
Awareness
Research
Support
Support
Risk-
Stratification
Stratification
Self-Care
Enabler
Enabler
Data Generation
Data Interpretation
Decision Influence
Caris Life
Sciences
Medicine
Illumina
Roche 454
Legend: Industry Segment
Molecular Profiling / Dx
Clinical Reference
Predictive Analytics
My Cancer
Genome
Elsevier
Clinical
UpToDate
Gene Insight
Compendia
Biosciences
IBM
Watson
N-of-One
23 and Me
Copyright Collabrx, Inc. 2012
NASDAQ CM: CLRX
Caris Life
13
Clinical
Support
Support
Public
Awareness
Awareness
Research
Support
Support
Risk-
Stratification
Stratification
Self-Care
Enabler
Enabler
Data Generation
Data Interpretation
Decision Influence
Foundation
Medicine
Illumina
Roche 454
Legend: Industry Segment
Molecular Profiling / Dx
Clinical Reference
Predictive Analytics
Compendia
Biosciences
IBM
23 and Me
Copyright Collabrx, Inc. 2012
NASDAQ CM: CLRX
14
NASDAQ CM: CLRX
Copyright Collabrx, Inc. 2012
Copyright Collabrx, Inc. 2012
NASDAQ CM: CLRX
15
•Expert insights on:
• Targets
• Treatment Guidelines
• Drugs
• Trials
• Literature.
•Links to:“
• Therapy Finder Advisor
and Board
and Board
• Learning About the
Science Behind the
Target
Science Behind the
Target
Treating Physician Portal
Patient
Portal
Portal
Test Result
(e.g.,ION TORRENT)
Content Engine
16
NASDAQ CM: CLRX
Copyright Collabrx, Inc. 2012
Drugs
Clinical Trials
“CollabRx has pioneered the development of a
scalable platform and process to provide
current, actionable, easily accessible, and highly
credible knowledge at the point of care to aid
physicians in developing a cancer treatment plan
based on tumor molecular profiles. We are
excited to include this key capability with our
molecular diagnostic tests.”
scalable platform and process to provide
current, actionable, easily accessible, and highly
credible knowledge at the point of care to aid
physicians in developing a cancer treatment plan
based on tumor molecular profiles. We are
excited to include this key capability with our
molecular diagnostic tests.”
Copyright Collabrx, Inc. 2012
NASDAQ CM: CLRX
17
- Ronnie Andrews, President
Medical Sciences, Life Technologies Corporation
¡ Thomas Mika, Chairman & CEO
§ Tegal, IMTEC, Cresap, NSF
¡ George Lundberg, MD, Editor-In-Chief
§ American Medical Association, WebMD, Medscape
¡ Gavin Gordon, MBA, PhD, Head of Bus Dev &
Alliances
Alliances
§ Harvard Medical School (professor; molecular
pathology)
pathology)
¡ Smruti Vidwans, PhD, Chief Scientist
§ McKinsey & Company (GSK, Roche), MIT, UCSF
¡ Randy Gobbel, PhD, Head of Engineering
§ PARC (XEROX), XEROX, MDL, UCSD
18
NASDAQ CM: CLRX
Copyright Collabrx, Inc. 2012
¡ Founded 2008 by Silicon Valley Tech Entrepreneurs
§ Approximately $10M Invested Capital
§ Acquired by Tegal Corporation (TGAL) on July 12, 2012
¡ NASDAQ CM: CLRX (as of September 27, 2012)
§ Cash: $6.2M as of September 30, 2012 (Q2-FY’13)
§ Liabilities: $0.5M Note to Sellers
§ Net Operating Loss (Estimates): ~ $100M Federal; $50M California
§ ~ 2 Million Total Shares Outstanding; ~2.6M fully-diluted
¡ Convergence of multiple mega trends
¡ Disruptive technology and approach
¡ No comparable micro-caps in this sector
¡ Goals for CY2013 - Expand strategic partnerships, product
development, and product launches for initial revenue
development, and product launches for initial revenue
19
NASDAQ CM: CLRX
Copyright Collabrx, Inc. 2012
Thomas R. Mika, Chairman & CEO
tmika@collabrx.com
415.248.5350 (office)
415-686-2198 (mobile)
Investor Relations Contact:
Robert Ferri
Robert Ferri Partners
580 California Street, Suite 1200
San Francisco, CA 94104
(415) 575-1589 (direct)
Robert Ferri Partners
580 California Street, Suite 1200
San Francisco, CA 94104
(415) 575-1589 (direct)
robert.ferri@robertferri.com
www.robertferri.com
CollabRx, Inc.
44 Montgomery St., Suite 800
San Francisco, CA 94104
www.collabrx.com
NASDAQ CM: CLRX
20
NASDAQ CM: CLRX
Copyright Collabrx, Inc. 2012